TLR7 and herpes labialis: The TLR7-agonist imiquimod and the mixed TLR7/8-agonist resiquimod induce interferon (IFN)α, and imiquimod is the first approved topically active TLR7 agonist used to treat human papilloma virus (HPV), but has failed to show significant efficacy against HSV2 infection [10–12], although cases have been reported with benefit of imiquimod 5% cream for treatment of herpes labialis and genital herpes [13, 14].